JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, announced involvement with two new research breakthroughs that demonstrate expande...
RAYUS Radiology, a leading national provider of advanced diagnostic and interventional medical imaging services, announces the latest addition to its line ...
The gold standard clinical assessment of treatment response is to measure changes in tumor volume over time. Typically, the RECIST (Response Evaluation Cri...
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammati...
The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by ...
Artificial intelligence continues to expand rapidly and a new computer vision algorithm is now available to Moscow radiologists in city hospitals. It analy...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agr...
Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- ...
Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today it has ex...
Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a st...
Zeon Corporation (Zeon; head office: Chiyoda-ku, Tokyo; President and CEO: Kimiaki Tanaka), through its subsidiary Zeon Specialty Materials Inc. (Californi...
Partnership to leverage the Helix® Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise Ad...
© 2025 Biopharma Boardroom. All Rights Reserved.
